Search review questions

Maximum voluntary contraction in myotonic dystrophy type 2 % · patients with muscular dystrophies

Adverse events · patients with muscular dystrophies

Global assessment of improvement felt better · patients with muscular dystrophies

Maximum voluntary contraction in mitochondrial diseases % · patients with metabolic myopathies

Maximum voluntary contraction in glycogen storage disease type V % · patients with metabolic myopathies

Impairment of activities of daily living (ADL) in glycogen storage disease type V Visual numeric scale. Scale from: 1 to 10. · patients with metabolic myopathies

Adverse events in mitochondrial diseases · patients with metabolic myopathies

ALS Functional Rating Scale (ALSFRS) score at 3 months Scale from: 0 to 40 (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease

Short‐Form‐36 Health Survey (SF‐36) score at 3 months Scale from: 0 to 100 (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease

Fatigue Severity Scale score at 3 months Scale from: 0 to 63 (lower is better). · people with amyotrophic lateral sclerosis or motor neuron disease

Manual Muscle Testing score at 3 months Right and left shoulder abduction, elbow flexion and extension, finger abduction and extension, hip flexion, knee flexion and extension, foot dorsiflexion and plantarflexion assessed and graded 0 to 5 Medica... · people with amyotrophic lateral sclerosis or motor neuron disease

Upper extremity maximum voluntary isometric contraction score at 3 months Quantitative Muscle Assessment (QMA) system. Data were normalized, summed and averaged to yield an U/E megascore (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease

Lower extremity maximum voluntary isometric contraction score at 3 months Quantitative Muscle Assessment (QMA) system. Data were normalized, summed and averaged to yield a L/E megascore (higher is better). · people with amyotrophic lateral sclerosis or motor neuron disease

Adverse effects related to the intervention · people with amyotrophic lateral sclerosis or motor neuron disease

At least 50% reduction in pain or equivalent · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

"Moderate" benefit At least 30% reduction in pain · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

Proportion below 30/100 mm on VAS · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

Patient Global Impression of Change much or very much improved · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

Adverse event withdrawals · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

Serious adverse events · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

Death · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)

Changes to the ALSFRS‐R scores at 12 months · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Changes to the MMT scores at 12 months · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Changes to FSS at 12 months · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Adverse events leading to cessation of treatment · patients with the treatment of amyotrophic lateral sclerosis or motor neuron disease

Short‐term overall improvement (three months or less) · patients with CTS

Adverse effects · patients with CTS

Short‐term improvement in pain and/or paraesthesia (after seven weeks of treatment) Scale from: zero to 10 · patients with CTS

Short‐term improvement in hand grip strength (change from baseline to seven weeks) · patients with CTS

Long‐term improvement in CTS symptoms (number of participants with complete remission of subjective symptoms) (six months · patients with CTS

Long‐term improvement in pain and/or paraesthesia (six months · patients with CTS

Long‐term improvement in hand grip strength (six months · patients with CTS

Mortality or tracheostomy at 12 months (pooled hazard ratio)(riluzole 100 mg) · patients with ALS/MND

Per cent mortality at 12 months (riluzole 100 mg) · patients with ALS/MND

Rate of decline of Norris Scale ‐ Norris Limb (riluzole 100 mg) · patients with ALS/MND

Rate of decline of Norris Scale ‐ Norris Bulbar (riluzole 100 mg) · patients with ALS/MND

Adverse event: nausea · patients with ALS/MND

Adverse event: asthenia · patients with ALS/MND

Adverse event: 3‐fold increase in alanine transferase · patients with ALS/MND

rhIGF‐I, 0.1 mg/kg/day ‐ survival at12 months · patients with amyotrophic lateral sclerosis/motor neuron disease

rhIGF‐I, 0.1 mg/kg/day ‐ change in AALSRS at 9 months · patients with amyotrophic lateral sclerosis/motor neuron disease

rhIGF‐I, 0.1 mg/kg/day ‐ change in SIP after 9 months · patients with amyotrophic lateral sclerosis/motor neuron disease

rhIGF‐I, all doses ‐ injection site pain · patients with amyotrophic lateral sclerosis/motor neuron disease

rhIGF‐I, all doses ‐ injection site inflammation/reaction · patients with amyotrophic lateral sclerosis/motor neuron disease

Tracheostomy‐free survival · patients with amyotrophic lateral sclerosis

ALSFRS‐R slope Change in ALSFRS‐R / month · patients with amyotrophic lateral sclerosis

FVC Slope Change in FVC / month · patients with amyotrophic lateral sclerosis

Change in sensory score after one year · patients with nerve damage in leprosy

Proportion of ulnar nerves with sensory improvement after one year · patients with nerve damage in leprosy

Change in motor score after one year · patients with nerve damage in leprosy